Privileged account security system and method for managing access

USPTO granted patent US12598187B2 to Saudi Arabian Oil Company for a system and method managing privileged account access. The technology disables privileged accounts upon creation and enables them only after user authentication for elevated rights requests, reducing the likelihood of system compromise. This is a routine IP event establishing enforceable patent rights for the assignee.

Atlassian patent, access controls for authenticated and public users

The USPTO granted Patent US12598189B2 to Atlassian Pty Ltd covering a content collaboration system that manages dual access controls for authenticated users and unauthenticated public users. The system provides synchronized content caching and hierarchical visibility controls for publicly accessible digital content across enterprise environments.

Salesforce multi-tenant data access control with cloud token security

USPTO granted Salesforce patent US12598193B2 covering fine granularity control of data access and usage across multi-tenant systems. The system validates user access requests against data source permissions and creates cloud-specific tokens converted from cloud-neutral tokens, establishing temporary IAM roles and policies with automatic expiration.

Network access using hardware-based security

USPTO granted patent US12598078B2 to Sophos Limited covering hardware-based security for network authentication. The patent describes endpoint devices using hardware-bound security systems to authenticate to enterprise networks, with cryptographically validated challenge-response protocols. The patent was applied for on February 15, 2023, under application number 18110051, with 20 claims granted.

Chronic rhinitis electrosurgical treatment, Olympus patent

The USPTO granted patent US12594116B2 to Olympus Winter & Ibe GmbH on April 7, 2026. The patent covers a method for treating chronic rhinitis using a handheld electrosurgical applicator for treatment of hypertrophic nasal conchae and/or submucosal ablation of the posterior nasal nerve to reduce cardinal symptoms. The patent was filed in July 2022 and includes 2 claims.

Medical systems and related methods for imaging material removal

The USPTO granted patent US12594124B2 to Boston Scientific Scimed, Inc. for a method of identifying material to be removed from a patient using medical imaging. The patent covers systems and methods for obtaining image data, analyzing it based on darkness, contrast, or saturation, and generating coded images to guide material removal with an insertion device.

Visualization system and method for ENT procedures

The USPTO granted patent US12594125B2 to Acclarent, Inc. covering a visualization system for ENT procedures that integrates image-guided surgery navigation with head-mounted displays. The system uses magnetic position tracking and camera-based image analysis to overlay surgical navigation data onto patient anatomy viewed through a transparent HMD screen. The patent includes 7 inventors and 15 claims.

Laceration system and device patent - Boston Scientific

USPTO granted Boston Scientific Patent US12594115B2 for a laceration device used in medical procedures. The patent covers a shaft with perforation and laceration electrodes, an outwardly extending barb, and associated electrical connectors for connection to a power source. The invention is assigned to Boston Scientific Medical Device Limited with four listed inventors.

Surgical instrument for colorectal polyp removal, US12594114B2

Surgical instrument for colorectal polyp removal, US12594114B2

Neuromodulation Systems and Methods for Enhanced Nerve Targeting

USPTO granted Medtronic Ireland Manufacturing Unlimited Company Patent No. US12594118B2 covering neuromodulation systems with enhanced nerve targeting capabilities. The patent discloses methods for positioning reference and ablation electrodes intravascularly, obtaining impedance measurements, and identifying electrode groups for treatment based on those measurements. Medtronic secured intellectual property protection for these neuromodulation innovations.